History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. The Globe and Mail
Covered in this story
What has happened since
- Medtronic is up 9.5% since this was published, 19 days ago.
- Johnson & Johnson is up 0.3% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Medtronic
- Mizuho: $92.2 → $115 by Sep 2027 · Outperform via Investing.com
- Stifel: $92.2 → $95 by Sep 2027 · Hold via Investing.com
- Needham: $92 → $114 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MDT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Medtronic →Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.